Name: Idelalisib
Price: 161.00 USD

- Overview
  - Idelalisib is the free base version of the compound. It is a small molecule inhibitor of phosphoinositide 3-kinase. It also inhibits other class I P13K enzymes. It also inhibits several signaling pathways, including B-cell receptor signaling.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Idelalisib blocks the delta isoform of the enzyme phosphoinositide 3-kinase signaling, P110δ . The result is decreased phosphorylation of Akt and other effectors. By blocking ongcogenic signaling, the compound has utility for B-cell malignancies.
- Properties
  - CAS Number
    
    870281-82-6
    
    Molecular Formula
    
    C22H18FN7O
    
    Molecular Weight
    
    415.42 g/mol
    
    Appearance
    
    Pale yellow to white solid powder
    
    Solubility
    
    DMSO (≥59.7 mg/ml)
    
    Other Properties
    
    Source: Synthetic
    Purity Level: ≥99% (by HPLC)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Cancer Applications: Cytotoxicity p110δ-positive multiple myeloma cells was induced by Idelalisib, but was non toxic to healthy PBMCs. The compound blocked in vitro capillary-like tube formation (angiogenesis). A hallmark of autophagy is LC3-II, and Idelalisib was also found to induce LC3-II (Ikeda et al, 2010).In cell-based assays with B-cell tumor lines and primary cells, Idelalisib had 240- to 2500-fold selectivity for P110δ over the other class I P13K isoforms. In SU-DHL-5, WSU-NHL, and CCRF-SB tumor cell lines, exposure to Idelalisib induced apoptosis, reflected in a 3- to 5-fold increase in annexin V staining. By blocking oncogenic signaling, the compound has utility for B-cell malignancies (Lannutti et al, 2011).